Five-year follow up of the ATS mechanical heart valve.

BACKGROUND AND AIM OF THE STUDY Between January 1, 1997 and December 31, 2001, a total of 342 patients underwent aortic valve replacement (AVR) or mitral valve replacement (MVR) with the ATS Medical prosthesis. The initial three-year phase of this study took place under a United States Food and Drug Administration-approved investigational device exemption study. The study aim was to determine the incidence of valve-related events in up to five years of follow up after valve implantation, and to assess patient disturbance from valve noise. METHODS Patients were consecutively enrolled to undergo AVR or MVR with the ATS prosthesis. Follow up studies were conducted by patient questionnaire and/or telephone call. Follow up was 96% complete. AVR was conducted in 246 patients (80 with coronary bypass), and MVR in 96 patients (29 with coronary bypass). RESULTS The overall operative mortality was 2.6% (n = 9; AVR 3.2%, n = 8; MVR 1.0%, n = 1), with two deaths being valve-related (0.6%). In 878 patient-years (pt-yr) of follow up (613 pt-yr for AVR; 265 pt-yr for MVR) there were an additional 22 deaths. Five deaths (0.6%/pt-yr) were valve-related: two were neuroembolic (both MVR), one from endocarditis (AVR), and two from bleeding events (both AVR). Late valve-related complications (>30 days) included 17 episodes of major bleeding (11 AVR, 1.8%/pt-yr; six MVR, 2.3%/pt-yr), five permanent neuroembolic events (four AVR, 0.7%/pt-yr; one MVR, 0.4%/pt-yr); 16 transient neuroembolic events (10 AVR, 1.6%/pt-yr; six MVR, 2.3%/pt-yr); three transient peripheral emboli (two AVR, 0.3%/pt-yr; one MVR, 0.4%/pt-yr); four paravalvular leaks (two AVR, 0.3%/pt-yr; two MVR, 0.8%/pt-yr); and one episode of valve thrombosis (MVR, 0.4%/pt-yr; AVR, 0%/pt-yr). Reoperation was required in two patients: one AVR (paravalvular leak, 0.2%/pt-yr) and one MVR (replacement due to thrombosis, 0.4%/pt-yr). CONCLUSION These results indicate that intermediate-term results with the ATS mechanical prosthesis continue to be excellent, though further long-term follow up is warranted.

[1]  R. Körfer,et al.  International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? , 2001, The Annals of thoracic surgery.

[2]  J. Hasenkam,et al.  Assessment of perceived mechanical heart valve sound level in patients. , 1999, The Journal of heart valve disease.

[3]  M. Shiono,et al.  Evaluation of valve sound and its effects on ATS prosthetic valves in patients' quality of life. , 2000, The Annals of thoracic surgery.

[4]  R. Emery,et al.  Replacement of the aortic valve in patients under 50 years of age: long-term follow-up of the St. Jude Medical prosthesis. , 2003, The Annals of thoracic surgery.

[5]  G. Tenderich,et al.  Low-dose international normalized ratio self-management: a promising tool to achieve low complication rates after mechanical heart valve replacement. , 2005, The Annals of thoracic surgery.

[6]  L. Cohn,et al.  Guidelines for reporting morbidity and mortality after cardiac valvular operations. , 1996, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  D. Nicoloff,et al.  Six years of experience with the St. Jude Medical valvular prosthesis. , 1985, Circulation.

[8]  R. Hall,et al.  Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. , 1995, European heart journal.

[9]  G. Grunkemeier,et al.  Statistical analysis of heart valve outcomes. , 2002, The Journal of heart valve disease.

[10]  A. Fraser,et al.  A New Scoring System to Determine Thromboembolic Risk After Heart Valve Replacement , 2003, Circulation.

[11]  J. Ennker,et al.  INR Self-Management Permits Lower Anticoagulation Levels After Mechanical Heart Valve Replacement , 2003, Circulation.

[12]  R. Hetzer,et al.  Impact of mechanical heart valve prosthesis sound on patients' quality of life. , 1996, The Annals of thoracic surgery.

[13]  R. Petersen,et al.  Long-term follow-up of the St. Jude Medical prosthesis in pediatric patients. , 1995, The Annals of thoracic surgery.

[14]  The initial United States experience with the ATS mechanical cardiac valve prosthesis. , 2001, The heart surgery forum.

[15]  A. Friedl,et al.  Intensity of oral anticoagulation after implantation of St. Jude Medical aortic prosthesis: analysis of the GELIA Database (GELIA 4) , 2001 .

[16]  Robert W Emery,et al.  The initial experience with the ATS Medical mechanical cardiac valve prosthesis. , 2003, The Annals of thoracic surgery.

[17]  F. Mohr,et al.  Prospectively Randomized Comparison of Different Mechanical Aortic Valves , 2000, Circulation.

[18]  J. Alpert,et al.  Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. , 2001, Chest.